Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Hutchison China MediTech Limited    HCM   KYG4672N1198

HUTCHISON CHINA MEDITECH LIMITED

(HCM)
  Report  
 SummaryQuotesNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (USD)
Sales 2019 195 M
EBIT 2019 -151 M
Net income 2019 -123 M
Finance 2019 160 M
Yield 2019 -
Sales 2020 213 M
EBIT 2020 -184 M
Net income 2020 -148 M
Finance 2020 18,7 M
Yield 2020 -
P/E ratio 2019 -24,9x
P/E ratio 2020 -18,8x
EV / Sales2019 15,3x
EV / Sales2020 14,7x
Capitalization 3 148 M
More Financials
Company
Hutchison China Meditech Limited is an investment holding company principally engaged in the manufacture and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Manufacturing Business segment is engaged in the manufacture and distribution of drug... 
Sector
Pharmaceuticals
Calendar
03/16Earnings Release
More about the company
Surperformance© ratings of Hutchison China MediTech L
Trading Rating : Investor Rating :
More Ratings
Latest news on HUTCHISON CHINA MEDITECH L
11/28Chi-Med's Elunate® (Fruquintinib Capsules) Included in the National Reimburse..
GL
11/28HUTCHISON CHINA MEDITECH : Elunate® Included in China NRDL
PU
11/25HUTCHISON CHINA MEDITECH : Chi-Med Highlights Presentations at 2019 ESMO Asia
PU
11/25Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancrea..
GL
11/25HUTCHISON CHINA MEDITECH : Surufatinib granted FDA orphan drug designation
PU
11/22HUTCHISON CHINA MEDITECH : Chi-Med Highlights Oral Presentations at 2019 ESMO As..
AQ
11/15Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations..
AQ
11/11Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic N..
GL
11/06International companies to host live webcasts at Deutsche Bank's Depositary R..
AQ
10/17HUTCHISON CHINA MEDITECH : Chi-Med highlights publication of Phase II data showi..
AQ
10/17Chi-Med highlights publication of Phase II data showing promising efficacy fo..
GL
10/04Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients w..
GL
09/30CK HUTCHISON : Hutchison China MediTech Shares in London Fall as Investor Plans ..
DJ
09/30CK Hutchison prices offering of Chi-Med share capital enabling deconsolidatio..
GL
09/30CK HUTCHISON : Hutchison China MediTech Shares in London Fall as Investor Plans ..
DJ
More news
News in other languages on HUTCHISON CHINA MEDITECH L

- No features available -

More news
Sector news : Pharmaceuticals - NEC
08:58aCSL : Bering Gets FDA Orphan Designation for Hizentra
DJ
08:21aCANOPY GROWTH : Constellation tightens grip on Canopy with CEO appointment
RE
07:12aMERCK AND : to Buy ArQule for $2.7 Billion, or $20/Share
DJ
07:09aSANOFI : Synthorx Shares Up 165% After Sanofi Buyout Offer
DJ
06:41aXBIOTECH : Sells Bermekimad to Janssen Biotech
DJ
More sector news : Pharmaceuticals - NEC
Chart HUTCHISON CHINA MEDITECH LIMITED
Duration : Period :
Hutchison China MediTech Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 6,99  $
Last Close Price 4,73  $
Spread / Highest target 61,7%
Spread / Average Target 47,8%
Spread / Lowest Target 19,6%
EPS Revisions
Managers
NameTitle
Christian Hogg Chief Executive Officer & Executive Director
Chi Keung To Chairman
Enrico Magnanelli Vice President & Head-International Operations
Chig Fung Cheng Chief Financial Officer & Executive Director
Wei Guo Su Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
HUTCHISON CHINA MEDITECH LIMITED0.00%3 144
JOHNSON & JOHNSON8.78%369 462
ROCHE HOLDING AG25.45%263 079
MERCK AND COMPANY16.28%226 211
PFIZER-12.28%211 902
NOVARTIS22.87%208 547